Conference Coverage

What Distinguishes MS From Its Mimics?


 

Suggested Reading

Costello DJ, Eichler AF, Eichler FS. Leukodystrophies: classification, diagnosis, and treatment. Neurologist. 2009;15(6):319-328.

Kleinfeld K, Mobley B, Hedera P, et al. Adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia: report of five cases and a new mutation. J Neurol. 2013;260(2):558-571.

Pawate S, Agarwal A, Moses H, Sriram S. The spectrum of Susac’s syndrome. Neurol Sci. 2009;30(1):59-64.

Pages

Recommended Reading

Retinal Measurements Predict 10-Year Disability in MS
MDedge Neurology
Telerehabilitation May Be As Effective As In-Person Rehabilitation in MS
MDedge Neurology
Can Neurologists Predict Long-Term Disability Trajectories in Primary Progressive MS?
MDedge Neurology
Does the EDSS Capture Cognitive Difficulties in Patients With MS?
MDedge Neurology
Durable Efficacy of Alemtuzumab: Five-Year Follow-Up of the CARE-MS Studies
MDedge Neurology
Arbaclofen Extended-Release Tablets Are Effective for MS Spasticity
MDedge Neurology
Ocrelizumab Increases Likelihood of No Evidence of Disease Progression
MDedge Neurology
European guidelines cover entire spectrum of MS treatment
MDedge Neurology
Siponimod curbs disability in secondary progressive multiple sclerosis
MDedge Neurology
Alemtuzumab, natalizumab found equally effective for relapsing-remitting MS
MDedge Neurology